David P. Harrington, PhD
Office phone: 617-632-3012
Preferred contact method: email
Area of ResearchNonparametric Methods for Survival Data, Collaborative Clinical Trials
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Harrington received his PhD in mathematics from the University of Maryland in 1976, has been a faculty member at DFCI and the Harvard School of Public Health since 1984, and has served as chair of the department since 1998. His research focuses on statistical issues that arise in clinical trials, with special focus on lymphoma, lung cancer, and the delivery of cancer care.
- Award for Teaching Excellence, Harvard School of Public Health, 1999
- Elected Fellow, Institute of Mathematical Statistics, 1993
- Elected Fellow, American Statistical Association, 1992
- Elected Member, International Statistical Institute, 1991
ResearchNonparametric Methods for Survival Data, Collaborative Clinical Trials
Our research focuses on two main areas: the computational and mathematical issues that arise in the design and analysis of clinical trials, and clinical trials examining the treatment of lymphoma, leukemia, and lung cancer.
Methodologic research in statistical issues concentrates on mathematical models for efficient designs of multicenter clinical trials of cancer treatment, the analysis of time-to-event data, and the design of population-based studies of cancer care. This research examines early-stopping for clinical trials, the analysis of high-dimensional data with event-time endpoints, and analytic methods for population-based methods of cancer care.
Collaborative research in cancer is conducted with investigators at the Dana-Farber/Harvard Cancer Center and the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). CanCORS is a national survey, funded by the National Cancer Institute, to study patterns of care in lung and colorectal cancer, with an emphasis on disparities in care by race, ethnicity, and age. Our department serves as the Statistical Coordinating Center for CanCORS.
- Joffe S, Harrington DP, George SL, Emanuel EJ, Budzinski LA, Weeks JC. Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ 2004;328:1463.
- Huang J, Harrington DP. Iterative partial least squares with right-censored data analysis: a comparison to other dimension reduction techniques. Biometrics 2005;61:17-24.
- International Myeloma Working Group (D. Harrington-participant). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Working Group. Br J Haematol 2003;121:749-57.
- Huang J, Harrington D. Dimension reduction in the linear model for right-censored data: predicting the change in HIV-1 RNA levels using clinical and protease gene mutation data. Lifetime Data Anal 2004;10:425-43.
- Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, Provenzale DT, Sandler RS, van Ryn M, Wallace RB, Weeks JC, West DW. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 2004;22:2992-6.
- Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-75.